Aging and Disease,
Journal Year:
2024,
Volume and Issue:
unknown, P. 0 - 0
Published: Jan. 1, 2024
Brain
insulin
resistance
has
recently
been
described
as
a
metabolic
abnormality
of
brain
glucose
homeostasis
that
proven
to
downregulate
receptors,
both
in
astrocytes
and
neurons,
triggering
reduction
uptake
glycogen
synthesis.
This
condition
may
generate
mismatch
between
brain's
energy
reserve
expenditure,
mainly
during
high
demand,
which
could
be
involved
the
chronification
migraine
and,
long
run,
at
least
certain
subsets
patients,
prodromic
phase
Alzheimer's
disease,
along
putative
physiopathological
continuum.
Indeed,
persistent
disruption
supply
neurons
eventually
impair
protein
folding,
an
energy-requiring
process,
promoting
pathological
changes
such
amyloid-β
deposition
tau
hyperphosphorylation.
Hopefully,
"neuroenergetic
hypothesis"
presented
herein
will
provide
further
insight
on
there
being
conceivable
bridge
chronic
elucidating
novel
potential
targets
for
prophylactic
treatment
diseases.
Aging,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 17, 2025
Background:
Alzheimer
Disease
(AD)
affects
more
than
50
million
people
worldwide,
with
10
new
diagnosis
each
year.
The
link
between
Sildenafil,
a
Phosphodiesterase-5
(PDE5)
inhibitor,
and
risk
of
AD
has
been
debated.
We
conducted
the
first
meta-analysis
on
association
Sildenafil
use
AD.
Methods:
searched
MEDLINE
Embase
from
inception
to
March
11,
2024
identify
cohort,
case-control
studies
comparing
frequency
in
patients
taking
those
without.
computed
ratios
(RR)
hazard
(HR)
accompanying
95%
Confidence
Intervals
(CIs)
for
study,
pooled
results
using
random-effects
meta-analysis.
Results:
Out
415
that
were
screened
initially,
5
comprising
885,380
included
analysis.
was
associated
reduced
developing
by
two-fold
compared
non-use
(HR:
0.47,
CI:
0.27-0.82,
p<0.001).
There
similar
reduction
PDE5
inhibitors
(RR:
0.55,
0.38-0.80,
p=0.002).
Conclusions:
Our
showed
is
two-fold.
Further
randomized
control
trials
ascertain
effect
pathology
would
be
useful.
Alzheimer s & Dementia,
Journal Year:
2025,
Volume and Issue:
21(3)
Published: March 1, 2025
Abstract
INTRODUCTION
Comorbid
conditions
associated
with
Alzheimer's
disease
(AD)
are
poorly
understood
regarding
timing
and
potential
impact
on
onset
progression.
METHODS
Medical
Information
Mart
for
Intensive
Care‐IV
electronic
health
records
from
2008
to
2019
were
examined.
The
study
identified
2527
AD
patients
(34.9%
male,
mean
age
80.27
years)
among
299,712
patients.
We
examined
the
of
12
cardiovascular
metabolic
diseases
relative
diagnosis.
Data
National
Coordinating
Center
validated
findings.
RESULTS
Hypertension
was
most
common
comorbidity,
diagnosed
1.09
years
before
AD.
Depression
only
comorbidity
after
start,
0.16
average.
had
greater
rates
hypertension,
hypercholesterolemia,
depression
compared
general
population.
DISCUSSION
findings
emphasize
early
detection
therapy
AD‐related
comorbidities,
notably
diseases.
temporal
link
between
these
suggests
opportunities
preventive
strategies
improved
care
pathways.
Highlights
Temporal
analysis
comorbidities
:
reveals
hypertension
hyperlipidemia
as
leading
precursors
AD,
typically
1
1.3
prior
onset,
while
emerges
predominantly
Unique
data
integration
Large‐scale
datasets
MIMIC‐IV
(
n
=
299,712)
NACC
51,836)
leveraged
identify
chronological
patterns
in
key
comorbid
Sex‐
age‐specific
insights
prevalence
peaks
at
80
86
years,
females
exhibiting
higher
LOAD
males.
a
post‐diagnostic
marker
Unlike
other
depression's
(0.16
diagnosis)
highlights
need
targeted
mental
interventions
Implications
Findings
suggest
that
managing
hyperlipidemia,
modifiable
midlife
may
delay
or
reduce
risk
development.
Comorbidity
variability
across
cohorts
hypercholesterolemia
showed
significantly
cohort
MIMIC‐IV,
reflecting
dataset‐specific
biases
regional
healthcare
differences.
Future
research
directions
Advocates
longitudinal,
multiethnic,
global
studies
refine
diagnostic
criteria
explore
tailored
conditions.
Frontiers in Pharmacology,
Journal Year:
2025,
Volume and Issue:
16
Published: April 3, 2025
Alzheimer’s
disease
(AD)
is
one
of
the
most
common
diseases
characterized
by
neurodegeneration
and
becoming
a
major
public
health
problem
worldwide.
AD
manifested
mainly
progressive
impairments
in
cognition,
emotion,
language
memory
elderly
population.
Many
treatment
strategies
have
been
explored
for
decades;
however,
there
still
no
effective
way
to
address
root
cause
pathogenesis,
only
target
symptoms
improve
patient
cognitive
outcomes.
Intracerebral
administration
difficult
because
challenges
posed
blood‒brain
barrier
(BBB).
NPs
are
materials
with
sizes
between
1
100
nm
that
can
biocompatibility,
extend
half-life,
transport
macromolecules,
be
delivered
across
BBB
central
nervous
system,
exhibit
good
targeting
capabilities.
provide
new
ideas
terms
their
antiaging,
antineuroinflammatory,
antioxidative,
nerve
repair-promoting
effects.
In
this
manuscript,
we
first
describe
relationship
BBB.
Second,
introduce
application
nanoparticles
treatment.
Finally,
summarize
faced
AD.
European Journal of Neuroscience,
Journal Year:
2024,
Volume and Issue:
59(11), P. 2915 - 2954
Published: April 15, 2024
Alzheimer's
disease
(AD)
is
a
neurodegenerative
condition
that
exhibits
gradual
decline
in
cognitive
function
and
prevalent
among
significant
number
of
individuals
globally.
The
use
small
interfering
RNA
(siRNA)
molecules
interference
(RNAi)
presents
promising
therapeutic
strategy
for
AD.
Lipid
nanoparticles
(LNPs)
have
been
developed
as
delivery
vehicle
siRNA,
which
can
selectively
suppress
target
genes,
by
enhancing
cellular
uptake
safeguarding
siRNA
from
degradation.
Numerous
research
studies
exhibited
the
effectiveness
LNP-mediated
reducing
amyloid
beta
(Aβ)
levels
animal
models
feasibility
employing
approach
AD
emphasized
encouraging
outcomes
reported
clinical
other
medical
conditions.
has
emerged
to
slow
down
or
even
reverse
progression
targeting
synthesis
tau
phosphorylation
genes
linked
condition.
Improvement
mechanism
determination
most
suitable
targets
are
crucial
efficacious
management
This
review
focuses
on
through
LNPs
AD,
based
available
literature.
Current Drug Targets,
Journal Year:
2024,
Volume and Issue:
25(11), P. 752 - 774
Published: July 23, 2024
:
Alzheimer's
disease
(AD)
is
a
debilitating
neurodegenerative
disorder
characterized
by
the
presence
of
amyloid-β
(Aβ)
plaques
and
tau-containing
neurofibrillary
tangles,
leading
to
cognitive
physical
decline.
Representing
majority
dementia
cases,
AD
poses
significant
burden
on
healthcare
systems
globally,
with
onset
typically
occurring
after
age
65.
While
most
cases
are
sporadic,
about
10%
exhibit
autosomal
forms
associated
specific
gene
mutations.
Neurofibrillary
tangles
Aβ
formed
misfolded
tau
proteins
peptides
contribute
neuronal
damage
impairment.
Currently,
approved
drugs,
such
as
acetylcholinesterase
inhibitors
N-methyl
D-aspartate
receptor
agonists,
offer
only
partial
symptomatic
relief
without
altering
progression.
A
promising
development
using
lecanemab,
humanized
IgG1
monoclonal
antibody,
an
immune
therapeutic
approach.
Lecanemab
demonstrates
selectivity
for
polymorphic
variants
binds
large
soluble
aggregates,
providing
potential
avenue
targeted
treatment.
This
shift
in
understanding
role
adaptive
response
pathogenesis
opens
new
possibilities
interventions
aiming
address
disease's
intricate
mechanisms.
review
aims
summarize
recent
advancements
pathophysiology
innovative
approaches,
valuable
insights
both
researchers
clinicians.
